Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.
Fingolimod is a sphingosine-1-phosphate (S1P) analogue that has been used in clinical trials as a systemic immunomodulatory therapy for multiple sclerosis. Fingolimod readily accesses the central nervous system, raising the issue of its direct effects on neural cells. We assessed the effects of active fingolimod on dissociated cultures of mature, myelin-producing oligodendrocytes (OLGs) derived from adult human brain. Human OLGs express S1P receptor transcripts in relative abundance of S1P5>S1P3>S1P1, with undetectable levels of S1P4. Low doses of fingolimod (100 pmol/L to 1 nmol/L) induced initial membrane elaboration (2 days), subsequent retraction (4 days), and recurrence of extension with prolonged treatment (8 days). Higher doses (10 nmol/L to 1 mumol/L) caused the opposite modulation of membrane dynamics. Retraction was rescued by co-treatment with the S1P3/S1P5 pathway antagonist, suramin, and was associated with RhoA-mediated cytoskeletal signaling. Membrane elaboration was mimicked using the S1P1 agonist SEW2871. Fingolimod rescued human OLGs from serum and glucose deprivation-induced apoptosis, which was reversed with suramin co-treatment and mimicked using an S1P5 agonist. High doses of fingolimod induced an initial down-regulation of S1P5 mRNA levels relative to control (4 hours), subsequent up-regulation (2 days), and recurrent down-regulation (8 days). S1P1 mRNA levels were inversely regulated compared with S1P5. These results indicate that fingolimod modulates maturity- and species-specific OLG membrane dynamics and survival responses that are directly relevant for myelin integrity.
Miron
Veronique E
VE
Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
Hall
Jeffery A
JA
Kennedy
Timothy E
TE
Soliven
Betty
B
Antel
Jack P
JP
D000328:Adult; D017209:Apoptosis / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D003599:Cytoskeleton / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D000068876:Fingolimod Hydrochloride; D005786:Gene Expression Regulation / Q000187:drug effects; D005947:Glucose / Q000172:deficiency; D006801:Humans; D009836:Oligodendroglia / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D011409:Propylene Glycols / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D049349:Receptors, Lysosphingolipid / Q000235:genetics / Q000378:metabolism; D044967:Serum; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors
D011409:Propylene Glycols; D012333:RNA, Messenger; D049349:Receptors, Lysosphingolipid; D000068876:Fingolimod Hydrochloride; D005947:Glucose; D013110:Sphingosine
J Neuroimmunol. 2004 Aug;153(1-2):108-21
15265669
Transplant Proc. 2005 Jan-Feb;37(1):107-9
15808562
Neuron. 1997 Jul;19(1):197-203
9247275
Biochem J. 1977 May 15;164(2):323-9
880240
Biochem Pharmacol. 2002 Oct 15;64(8):1243-50
12234605
J Immunol. 2005 Oct 1;175(7):4320-30
16177072
Glia. 2007 Jan 15;55(2):130-43
17078030
J Neurosci. 2005 Feb 9;25(6):1459-69
15703400
Am J Transplant. 2005 Nov;5(11):2649-59
16212624
J Neurochem. 2006 Mar;96(6):1616-25
16441511
N Engl J Med. 2006 Sep 14;355(11):1124-40
16971719
Nat Rev Neurosci. 2002 Sep;3(9):705-14
12209119
Glia. 2007 Dec;55(16):1656-67
17876806
J Biol Chem. 2003 Nov 28;278(48):47408-15
13129923
Ann Neurol. 2008 Jan;63(1):61-71
17918267
Mol Biol Cell. 1999 Apr;10(4):1179-90
10198065
Neuroscience. 2003;116(4):1053-62
12617946
FASEB J. 2004 Mar;18(3):551-3
14715694
Brain. 2004 Dec;127(Pt 12):2636-48
15509624
Br J Pharmacol. 2003 Feb;138(3):481-93
12569073
Biochim Biophys Acta. 1968 Oct 22;164(2):285-93
4305490
J Pharmacol Exp Ther. 2007 Nov;323(2):469-75
17682127
J Neurochem. 2003 Nov;87(4):947-57
14622125
Nat Rev Neurosci. 2005 Sep;6(9):683-90
16136172
Acta Neuropathol. 1984;64(2):172-5
6475502
Ann N Y Acad Sci. 2000 Apr;905:118-31
10818448
J Biol Chem. 1999 Jul 2;274(27):18997-9002
10383399
J Cell Biol. 2004 Aug 2;166(3):381-92
15289497
Blood. 2003 Jun 15;101(12):4909-15
12586615
J Cell Biochem. 2004 Aug 1;92(5):913-22
15258915
J Clin Invest. 2004 Dec;114(11):1531-7
15578083
J Exp Med. 1996 Dec 1;184(6):2361-70
8976190
J Immunol. 2005 Dec 15;175(12):7973-80
16339533
Biochem J. 1974 Apr;140(1):99-109
4141622
Glia. 2004 Jan 1;45(1):17-27
14648542
Curr Opin Neurobiol. 2007 Oct;17(5):533-40
17923405
Neuroscientist. 2007 Oct;13(5):486-91
17901257
Science. 2002 Apr 12;296(5566):346-9
11923495
FASEB J. 2007 May;21(7):1503-14
17255471
Brain Pathol. 2007 Apr;17(2):210-8
17388952
Nature. 2004 Jan 22;427(6972):355-60
14737169
Braz J Med Biol Res. 2005 May;38(5):683-94
15917949
Trends Mol Med. 2006 Feb;12(2):65-75
16406843
J Biol Chem. 2005 Mar 18;280(11):9833-41
15590668
J Biol Chem. 2007 Feb 16;282(7):4310-4317
17166850
J Immunol. 2002 Oct 15;169(8):4084-7
12370333
J Pharmacol Exp Ther. 2007 Nov;323(2):626-35
17726159